Skip to content

Circulating Tumor Cells as Biomarker for Monitoring Treatment Response After Surgery in Early Breast Cancer Patients -Towards Improving Patient Well Being

Circulating Tumor Cells as Biomarker for Monitoring Treatment Response After Surgery in Early Breast Cancer Patients Towards Improving Patients Well Being - NILL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094661
Enrollment
48
Registered
2025-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C500- Malignant neoplasm of nipple and areola Health Condition 2: C501- Malignant neoplasm of central portion of breast Health Condition 3: C502- Malignant neoplasm of upper-innerquadrant of breast Health Condition 4: C503- Malignant neoplasm of lower-innerquadrant of breast Health Condition 5: C504- Malignant neoplasm of upper-outerquadrant of breast Health Condition 6: C505- Malignant neoplasm of lower-outerquadrant of breast Health Condition 7: C506- Malignant neoplasm of

Interventions

Intervention1: Surgery: Pre- operative samples will collected for circulating tumor cells followed by surgery. ,24 hours after surgery blood sample will be collected for checking the CTC . Control Int

Sponsors

Dr Rakesh S Ramesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and female breast cancer patients 2.Patients undergoing Breast conservation surgery, Modified radical mastectomy or Simple mastectomy 3.Patients undergone neoadjuvant chemotherapy 4.Ductal & Lobular carcinoma In situ or Invasive

Exclusion criteria

Exclusion criteria: 1.Second surgery 2.Recurrent disease 3.Metastatic disease 4.Benign breast lumps, sarcoma

Design outcomes

Primary

MeasureTime frame
Fall in CTC after Surgical intervention in Breast Cancer Patients , Reduction in cancer worry as Patient reported outcome measure after surgery, Minimum Residual Disease burden will be reduced there b y improving the survival of breast cancer patients.Timepoint: 1.Baseline (Pre-surgery): First CTC blood sample collection (to establish baseline CTC count). Assessment of cancer worry (Patient Reported Outcome Measure PROM). 2.24 hours post-surgery: Second CTC blood sample collection. Assessment in cancer worry (PROM).

Secondary

MeasureTime frame
NIllTimepoint: NIll

Countries

India

Contacts

Public ContactDr Rakesh S Ramesh

St Johns Medical college Hospital, Bengaluru

srakesh99@yahoo.co.in9980007455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026